Notice Number: NOT-CA-19-001
Key Dates
Release Date: October 10, 2018
Response Date: November 18, 2018
None
Issued by
National Cancer Institute (NCI)
Purpose
The NCI is seeking broad input from the scientific community to identify areas of need and opportunity for small cell lung cancer (SCLC). This input is requested to identify potential areas of emphasis in consideration of the renewal of the current funding opportunity announcements for SCLC ( PAR-16-049 , PAR-16-051 ).
Background
In 2017, the NCI launched the SCLC Consortium to improve prevention, diagnosis, and treatment of SCLC and understand mechanisms of treatment resistance. The SCLC Consortiumincludes a central U24 coordinating center and 13 U01 projects, of which six are focused on prevention and seven on therapy.
Despite the extraordinary progress of the past few years, our knowledge about SCLC is still too limited to effectively intervene preventively or therapeutically. To help identify the needs and priorities in SCLC, the NCI is seeking comments from the SCLC researchers and stakeholders regarding the current challenges and opportunities that are most likely to propel this field forward for the greatest benefit.
Information Requested
All stakeholders with an interest in improving the understanding of the biology, prevention, and treatment of SCLC are invited to comment on the priority research areas and needs that if addressed, would accelerate SCLC understanding and intervention.
The NCI is seeking information that includes, but is not limited to, the following areas:
- The critical areas of SCLC biology that need to be understood to advance effective or novel interventions.
- The key rate-limiting areas of knowledge that are slowing the understanding of therapy resistance and the development of novel agents, where additional focus is needed.
- Resources currently not available that would accelerate understanding of SCLC.
- New technologies not currently being applied in a significant manner that may provide new understanding of SCLC biology or interventions
Submitting a Response
All responses must be submitted to rjohnso2@mail.nih.gov by November 18 , 2018.
Please include the Notice number in the subject line. Response to this RFI is voluntary. Responders are free to address any or all of the categories listed above. The submitted information will be reviewed by NIH staff. Please do not include any proprietary, classified, confidential, and/or sensitive information in your response. The NIH will use the information submitted in response to this RFI at its discretion and will not provide comments to any responder's submission. The collected information may appear in reports and may be shared publicly on an NIH website. The Government reserves the right to use any non-proprietary technical information in summaries of the state-of-the-science, and any resultant solicitation(s). This RFI is for information and planning purposes only and should not be construed as a solicitation or as an obligation on the part of the Federal Government, the NIH, or individual NIH Institutes and Centers, including the NCI. No basis for claims against the U.S. Government shall arise as a result of a response to this request for information or from the Government’s use of such information.
Inquiries
Please direct all inquiries to:
Ron Johnson, Ph. D.
National Cancer Institute (NCI)
Telephone: 240-276-6250
Email: rjohnso2@mail.nih.gov
Suzanne Forry, Ph. D.
National Cancer Institute (NCI)
Telephone: 240-276-5922
Email: forryscs@mail.nih.gov
and Human Services (HHS)
